Table 2. Cumulative extracolonic cancer incidences for *MLH1* pathogenic variant carriers.										
Study	**Gender**	**20y**	**30y**	**40y**	**50y**	**60y**	**65y**	**70y**	**75y**	**80y**
ENDOMETRIAL CANCER										
General population[1]										3.1
Dominguez Valentin 2023	Female	0	2.0 (1.0 to 4.2)	14.9 (11.6 to 19.1)	28.4 (23.6 to 33.9)	31.7 (26.5 to 37.7)	35.8 (29.9 to 42.5)	37.2 (30.9 to 44.3)		
Fummey 2024	Female	0	0	7.7 (2.6 to 22.1)	23.2 (12.3 to 41.3)	27.7 (15.2 to 47.2)	27.7 (15.2 to 47.2)	43.7 (24.5 to 69.1)	43.7 (24.5 to 69.1)	
OVARIAN CANCER										
General population[1]										1.1
Dominguez Valentin 2023	Female		1.4 (0.6 to 3.5)	4.4 (2.7 to 7.2)	7.4 (4.9 to 11.1)	8 (5.3 to 12)	8 (5.3 to 12)	8 (5.3 to 12)		
GASTRIC CANCER										
General population[1]										0.8
Dominguez Valentin 2023	Male	0	0	0.7 (0.2 to 2.2)	2.4 (1.2 to 4.6)	2.8 (1.5 to 5.2)	5.5 (3.3 to 9.3)	8.9 (5.5 to 14.4)		
	Female	0	0.3 (0.2 to 0.3)	0.5 (0.1 to 1.9)	1.0 (0.4 to 2.7)	2 (1 to 4.2)	2.9 (1.5 to 5.6)	4.3 (2.3 to 7.9)		
SMALL BOWEL CANCER										
General population[1]										0.3
Dominguez Valentin 2023	Male	0	0.3 (0 to 1.9)	1.5 (0.7 to 3.2)	3.6 (2.1 to 6.1)	4.4 (2.6 to 7.2)	6.6 (4.1 to 10.3)			
	Female	0	0.9 (0.3 to 2.8)	1.6 (0.7 to 3.5)	2.5 (1.3 to 4.6)	2.5 (1.3 to 4.6)	3.8 (2.2 to 6.7)			
BILE DUCT / BILIARY TRACT CANCER										
General population[1]										Not available
Dominguez Valentin 2023	Male						2.9 (1.5 to 5.6)			
	Female						1.5 (0.7 to 3.3)			
PANCREATIC CANCER										
General population[1]										1.7
Dominguez Valentin 2023	Male	0	0.7 (0.2 to 2.2)	0.7 (0.2 to 2.2)	1.3 (0.5 to 3.1)	1.1 (0.4 to 2.9)	4.0 (2.2 to 7.3)	4.0 (2.2 to 7.3)		
	Female	0	0.4	0.4	1.2	1.9	1.5	1.5		

Study	Sex								General population[1]
			(0.1 to 1.7)	(0.1 to 1.7)	(0.5 to 2.8)	(0.9 to 4)	(0.7 to 3.3)	(0.7 to 3.3)	
URERTER AND KIDNEY CANCER									
General population[1]									Not available
Dominguez Valentin 2023	Male	**0**	**0**	0.7 (0.2 to 2.2)	1.3 (0.5 to 3.2)	2.5 (1.3 to 5.1)	3.7 (1.9 to 6.9)	4.5 (2.4 to 8.6)	
	Female	**0**	0.3 (0 to 1.8)	0.5 (0.1 to 1.9)	0.7 (0.2 to 2.2)	1.7 (0.8 to 3.8)	2.2 (1.0 to 4.6)	2.9 (1.4 to 6.0)	
URINARY BLADDER CANCER									
General population[1]									2.3
Dominguez Valentin 2023	Male	0	0	0.5 (0.1 to 1.9)	2.1 (1.0 to 4.3)	3.3 (1.8 to 6.1)	3.8 (2.1 to 6.9)	5.6 (3.1 to 10.0)	
	Female	0	0	0.2 (0 to 1.5)	1.0 (0.4 to 2.7)	1.3 (0.6 to 3.2)	2.7 (1.3 to 5.5)	4.8 (2.6 to 8.9)	
PROSTATE CANCER									
General population[1]									12.6
Dominguez Valentin 2023	Male	0	0	0.2 (0 to 1.7)	2.9 (1.5 to 5.4)	5.3 (3.2 to 8.7)	7.6 (4.8 to 11.8)	15.6 (10.7 to 22.6)	
BREAST CANCER									
General population[1]									Not reported
Dominguez Valentin 2023	Female	0	0.6 (0.1 to 2.3)	3.0 (1.7 to 5.1)	7.4 (5.3 to 10.4)		10.4 (7.6 to 14.1)	12.4 (9.1 to 16.9)	
Fummey 2024	Female	0	2.6 (0.4 to 17.0)	5.2 (1.3 to 19.2)	5.2 (1.3 to 19.2)	5.2 (1.3 to 19.2)	10.1 (3.2 to 29.9)	22.4 (9.4 to 48.0)	22.4 (9.4 to 48.0)
BRAIN CANCER									
General population[1]									0.5
Dominguez Valentin 2023	Male	0	0	0	0	0	0.6 (0.1 to 3.9)	0.6 (0.1 to 3.9)	
	Female	0	0.3 (0 to 1.8)	0.7 (0.2 to 2.1)	0.9 (0.3 to 2.4)	0.9 (0.3 to 2.4)	1.4 (0.5 to 3.4)	1.4 (0.5 to 3.4)	
Combined: GASTRIC, SMALL BOWEL, BILE DUCT, GALLBLADDER AND PANCREAS CANCER									
Dominguez Valentin 2023	Male	0 (0 to 3.1)	0.8 (0.2 to 4)	2.1 (1 to 5.4)	5.1 (3.1 to 8.8)		15.7 (11.2 to 22)	21.8 (16 to 29.9)	
	Female	0 (0 to 2.6)	1.2 (0.4 to 4)	1.8 (0.7 to 4.7)	4.5 (2.7 to 7.8)		8.4 (5.5 to 13)	11 (7.4 to 16.9)	

Bijlage: Tables 2 to 5, bij module Extracolonische kankerrisico en surveillance bij het Lynch syndroom
Richtlijn Erfelijke darmkanker: Lynch syndroom, polyposis en familiair darmkanker 2025

Data indicate the cumulative risk and 95% confidence interval.

[1] Data extracted from NCCN guideline 'Genetic/Familial High-Risk Assessment: Colorectal, Endometrial and Gastric' version 3.2024. Reflect lifetime risk data.

[2] Data presented of the full cohorts.

Table 3. Cumulative extracolonic cancer incidences for *MSH2* pathogenic variant carriers.										
Study	Gender	20y	30y	40y	50y	60y	65y	70y	75y	80y
ENDOMETRIAL CANCER										
General population[1]										3.1
Dominguez Valentin 2023	Female	0	2.0 (0.8 to 4.8)	18.1 (13.9 to 23.5)	33.9 (28.0 to 40.5)	37.6 (31.3 to 44.8)	42.1 (35.0 to 50.1)	44.1 (36.3 to 52.7)		
Fummey 2024	Female	0	0	14.4 (4.9 to 38.2)	14.4 (4.9 to 38.2)	14.4 (4.9 to 38.2)	23.7 (9.0 to 54.1)	23.7 (9.0 to 54.1)	23.7 (9.0 to 54.1)	
OVARIAN CANCER										
General population[1]										1.1
Dominguez Valentin 2023	Female	0	1.6 (0.6 to 4.2)	8.3 (5.5 to 12.4)	9.7 (6.6 to 14.2)	10.6 (7.2 to 15.6)	13.4 (8.9 to 20.1)	13.4 (8.9 to 20.1)		
GASTRIC CANCER										
General population[1]										0.8
Dominguez Valentin 2023	Male	0	0	0.3 (0 to 1.9)	3.0 (1.6 to 5.7)	4.3 (2.5 to 7.6)	5.0 (2.9 to 8.5)	4.0 (2.1 to 7.4)		
	Female	0	0	0.5 (0.1 to 2.1)	1.6 (0.7 to 3.5)	2.6 (1.4 to 5)	3.1 (1.7 to 5.9)	4.0 (2.1 to 7.4)		
SMALL BOWEL CANCER										
General population[1]										0.3
Dominguez Valentin 2023	Male	0	0.7 (0.2 to 2.6)	0.9 (0.3 to 2.9)	3.6 (2.0 to 6.4)	4.5 (2.6 to 7.6)	7.0 (4.3 to 11.3)	7.0 (4.3 to 11.3)		
	Female	0	0	1.4 (0.6 to 3.3)	2.5 (1.3 to 4.7)	3.2 (1.8 to 5.6)	3.7 (2.1 to 6.4)	3.7 (2.1 to 6.4)		
BILE DUCT / BILIARY TRACT CANCER										
General population[1]										Not available
Dominguez Valentin 2023	Male	0	0	0.3 (0 to 1.9)	0.6 (0.1 to 2.2)	1 (0.3 to 3.2)	2.3 (0.9 to 5.7)	4.6 (2.0 to 10.2)		
	Female	0	0	0	0.8 (0.3 to 2.4)	0.8 (0.3 to 2.4)	0.8 (0.3 to 2.4)	2.4 (0.9 to 6.5)		
PANCREATIC CANCER										
General population[1]										1.7
Dominguez Valentin 2023	Male	0	0	0	0.9 (0.3 to 2.9)	1.4 (0.5 to 3.7)	3.3 (1.5 to 7.1)	3.3 (1.5 to 7.1)		

Bijlage: Tables 2 to 5, bij module Extracolonische kankerrisico en surveillance bij het Lynch syndroom
Richtlijn Erfelijke darmkanker: Lynch syndroom, polyposis en familiair darmkanker 2025

	Female	0	0	0.3 (0 to 1.9)	0.5 (0.1 to 2.1)	1.2 (0.5 to 3.3)	2.7 (1.3 to 5.8)	3.5 (1.7 to 7.3)
URETER AND KIDNEY CANCER									
General population[1]								Not available
Dominguez Valentin 2023	Male	0	0	1.7 (0.8 to 3.7)	6.8 (4.5 to 10.2)	11.5 (8.2 to 16)	13.4 (9.7 to 18.5)	15.8 (11.2 to 22.0)
	Female	0	0	1.9 (0.9 to 4.0)	5.1 (3.3 to 7.9)	9.7 (6.9 to 13.5)	13.9 (10.2 to 18.6)	19.5 (14.6 to 25.9)
URINARY BLADDER CANCER									
General population[1]								2.3
Dominguez Valentin 2023	Male	0	0	1.1 (0.4 to 3.0)	4.6 (2.7 to 7.6)	5.9 (3.7 to 9.4)	7.2 (4.6 to 11.3)	13.1 (8.3 to 20.3)
	Female	0	0.4 (0.1 to 3.1)	1.5 (0.6 to 3.7)	2.6 (1.3 to 4.9)	4.7 (2.8 to 7.7)	6.2 (3.9 to 9.8)	9.4 (6.0 to 14.5)
PROSTATE CANCER									
General population[1]								12.6
Dominguez Valentin 2023	Male	0	0	0.8 (0.3 to 2.5)	6.6 (4.4 to 10.0)	10.6 (7.5 to 15)	16.4 (12.0 to 22.1)	24.0 (17.8 to 32.0)
BREAST CANCER									
General population[1]								Not reported
Dominguez Valentin 2023	Female	0	1.2 (0.4 to 3.7)	3.4 (1.9 to 6.1)	7.4 (5.1 to 10.7)		13.2 (9.7 to 17.7)	15.5 (11.5 to 20.9)
Fummey 2024	Female	0	0	0	0	6.8 (1.0 to 39.1)	6.8 (1.0 to 39.1)	6.8 (1.0 to 39.1)	6.8 (1.0 to 39.1)
BRAIN CANCER									
General population[1]								0.5
Dominguez Valentin 2023	Male	0	0.4 (0.1 to 3.0)	1.3 (0.5 to 3.5)	1.9 (0.9 to 4.3)	3.3 (1.7 to 6.3)	3.3 (1.7 to 6.3)	6.6 (3.4 to 12.4)
	Female	0	0.9 (0.2 to 3.5)	0.9 (0.2 to 3.5)	1.4 (0.5 to 3.8)	1.4 (0.5 to 3.8)	1.4 (0.5 to 3.8)	2.2 (0.8 to 5.7)

Data indicate the cumulative risk and 95% confidence interval.

[1] Data extracted from NCCN guideline 'Genetic/Familial High-Risk Assessment: Colorectal, Endometrial and Gastric' version 3.2024. Reflect lifetime risk data.

[2] Data presented of the full cohorts.

Bijlage: Tables 2 to 5, bij module Extracolonische kankerrisico en surveillance bij het Lynch syndroom
Richtlijn Erfelijke darmkanker: Lynch syndroom, polyposis en familiair darmkanker 2025

Table 4. Cumulative extracolonic cancer incidences for *MSH6* pathogenic variant carriers.										
Study	Gender	20y	30y	40y	50y	60y	65y	70y	75y	80y
ENDOMETRIAL CANCER										
General population[1]										3.1
Dominguez Valentin 2023	Female		0	2.2 (0.5 to 8.3)	10.3 (6.0 to 17.5)	25.1 (18.2 to 33.9)	32.1 (24.2 to 41.7)	45.7 (36.3 to 56.1)	49.6 (39.5 to 60.6)	
Werf-'t Lam 2025[2]	Female	0% (0%-0.6%)	0.1% (0%-1.4%)	0.9% (0.4%-11.1%)	5% (3.3%-24.2%)			13.3% (8.8%-30%)		23.4% (15.4%-43%)
OVARIAN CANCER										
General population[1]										1.1
Dominguez Valentin 2023[2]	Female		0	1.1 (0.2 to 7.4)	1.9 (0.5 to 7.5)	2.9 (0.9 to 8.7)	2.9 (0.9 to 8.7)	6.3 (2.6 to 15.2)	6.3 (2.6 to 15.2)	
Werf-'t Lam 2025[2]	Female		0.4 (0.2-1.2)	1.5 (0.5-4)	3.5 (1.3-9.1)	5.1 (2-12.8)		5.6 (2.4-13.6)		6.4 (3-14.8)
GASTRIC CANCER										
General population[1]										0.8
Dominguez Valentin 2023	Male		0	0	0	0.7 (0.1 to 4.9)	0.7 (0.1 to 4.9)	0.7 (0.1 to 4.9)	0.7 (0.1 to 4.9)	
	Female		0	0	0	0	0.7 (0.1 to 4.7)	0.7 (0.1 to 4.9)	0.7 (0.1 to 4.9)	
SMALL BOWEL CANCER										
General population[1]										0.3
Dominguez Valentin 2023	Male		0	0	0	0.7 (0.1 to 4.8)	0.7 (0.1 to 4.8)	1.6 (0.4 to 6.5)	2.8 (0.9 to 8.7)	
	Female		0	0	0	0.6 (0.1 to 4.0)	0.6 (0.1 to 4)	0.6 (0.1 to 4.0)	0.6 (0.1 to 4.0)	
Werf-'t Lam 2025[2]	Male									0.2 (0-2.8)
	Female									0.1 (0.1-1.9)
BILE DUCT / BILIARY TRACT CANCER										
General population[1]										Not available
Dominguez Valentin 2023	Male		0	0	0	0	0	0	0	
	Female		0	0	0	0	0	0	0	
PANCREATIC CANCER										
General population[1]										1.7
Dominguez Valentin 2023	Male		0	0	0	0	0	0	1.2 (0.2 to 8.1)	
	Female		0	0	0.7	0.7	0.7	2.2	2.2	

Bijlage: Tables 2 to 5, bij module Extracolonische kankerrisico en surveillance bij het Lynch syndroom
Richtlijn Erfelijke darmkanker: Lynch syndroom, polyposis en familiair darmkanker 2025

Study	Sex								
				(0.1 to 4.8)	(0.1 to 4.8)	(0.1 to 4.8)	(0.7 to 6.8)	(0.7 to 6.8)	
URETER AND KIDNEY CANCER									
General population[1]									Not available
Dominguez Valentin 2023	Male	0	0	0	1.4 (0.3 to 5.4)	1.4 (0.3 to 5.4)	3.3 (1.2 to 8.7)	3.3 (1.2 to 8.7)	
	Female	0	0	0	1.2 (0.3 to 4.6)	3.2 (1.3 to 7.4)	3.9 (1.8 to 8.6)	3.9 (1.8 to 8.6)	
URINARY BLADDER CANCER									
General population[1]									2.3
Dominguez Valentin 2023	Male	0	0	0.8 (0.1 to 5.6)	1.5 (0.4 to 5.8)	3.0 (1.1 to 7.9)	3.0 (1.1 to 7.9)	9.0 (4.7 to 16.9)	
	Female	0	0	0	1.2 (0.3 to 4.5)	1.8 (0.6 to 5.6)	2.6 (1.0 to 6.8)	2.6 (1.0 to 6.8)	
UROTHELIAL CANCER, INCLUDING URETER, KIDNEY AND URINARY BLADDER									
General population[1]									Not reported
Werf-'t Lam 2025[2]	Male	0 (0-0.1)	0.1 (0.1-0.3)	0.5 (0.3 - 1)	1.7 (0.9-3.4)		4.7 (2.4-9.0)	10.1 (5.2-18.8)	
	Female	0 (0-0.1)	0.1 (0.1-0.2)	0.3 (0.1-0.5)	0.8 (0.4-1.7)		2.0 (1.0 - 4.0	4.1 (2.1 - 8.1)	
PROSTATE CANCER									
General population[1]									12.6
Dominguez Valentin 2023	Male	0	0	0	1.4 (0.4 to 5.5)	3 (1.1 to 7.7)	5.8 (2.8 to 11.8)	7.0 (3.5 to 13.7)	
Werf-'t Lam 2025[2]	Male	0	0	0.1 (0.1-0.3)	1.7 (0.8-3.4)		7.8 (3.8-15.1)	16.6 (8.4-30.6)	
BREAST CANCER									
General population[1]									Not reported
Dominguez Valentin 2023	Female	0	0	2.3 (0.8 to 7.1)	6.5 (3.5 to 11.7)		9.3 (5.6 to 15.3)	15.1 (9.7 to 23.1)	
Fummey 2024	Female	0	1.3 (0.3 to 5.1)	2.0 (0.6 to 6.0)	4.8 (2.3 to 9.7)	4.8 (2.3 to 9.7)	8.3 (4.4 to 15.2)	10.2 (5.5 to 18.5)	16.5 (7.2 to 35.3)
Werf-'t Lam 2025[2]	Female	0.1 (0.1-0.2)	0.7 (0.4-1.4)	2.5 (1.4-4.6)	5 (2.8-9)		8 (4.5-14.3)	10.8 (6.2-19)	
BRAIN CANCER									
General population[1]									0.5
Dominguez Valentin 2023	Male	0	0	0	0.8 (0.1 to 5.3)	0.8 (0.1 to 5.3)	0.8 (0.1 to 5.3)	0.8 (0.1 to 5.3)	
	Female	0	0	0	1.2 (0.3 to 4.6)	1.2 (0.3 to 4.6)	1.2 (0.3 to 4.6)	1.2 (0.3 to 4.6)	

Bijlage: Tables 2 to 5, bij module Extracolonische kankerrisico en surveillance bij het Lynch syndroom
Richtlijn Erfelijke darmkanker: Lynch syndroom, polyposis en familiair darmkanker 2025

Study	Gender						
Werf-'t Lam 2025[3]	Male	0.1 (0-0.4	0.2 (0.1-0.8)	0.4 (0.1-1.5)	0.7 (0.2-2.8)	1.2 (0.3-4.7)	1.8 (0.5-7.2)
	Female	0	0.1 (0-0.4)	0.2 (0.1-0.9)	0.4 (0.1-1.7)	0.7 (0.2-2.8)	1.1 (0.3-4.4)
Combined: GASTRIC, SMALL BOWEL, BILE DUCT, GALLBLADDER AND PANCREAS CANCER							
Werf-'t Lam 2025[2]	Male	0	0	0.2 (0.1-0.3)	0.7 (0.3-1.6)	2.2 (1-4.8)	4.9 (2.2-10.8)
	Female	0	0	0.1 (0.1-0.3)	0.6 (0.3-1.4)	1.9 (0.8-4.3)	4.2 (1.8 - 9.4)

Data indicate the cumulative risk and 95% confidence interval.

[1] Data extracted from NCCN guideline 'Genetic/Familial High-Risk Assessment: Colorectal, Endometrial and Gastric' version 3.2024. Reflect lifetime risk data.

[2] Dutch cohort study, under review (online available in the repository): a retrospective cohort study of 360 families with 1117 known MSH6 LP/P carriers identified in the Netherlands between 1995 and 2020. Cumulative risks (CRs) were estimated using segregation analysis, appropriately adjusted for ascertainment.

Table 5. Cumulative extracolonic cancer incidences for *PMS2* pathogenic variant carriers.								
Study	Gender	30y	40y	50y	60y	65y	70y	75y	80y
ENDOMETRIAL CANCER									
General population[1]									3.1
Dominguez Valentin 2023	Female	0	0	0	9.9 (3.8 to 24.3)	12.7 (5.5 to 27.9)	12.7 (5.5 to 27.9)	21.2 (8.5 to 46.9)	
Ten Broeke 2018[3]	Female	0.04 (0.02-0.07)	0.2 (0.1-0.5)	1.2 (0.6-2.3)	4.4 (2.3-8.3)	6.6 (3.5-12)	8.8 (4.7-16)	11 (5.9-20)	13 (7 to 24)
Fummey 2024	Female	0	0	0	1.3 (0.4 to 4.0)	1.9 (0.7 to 5.9)	2.6 (1.1 to 6.3)	2.6 (1.1 to 6.3)	2.6 (1.1 to 6.3)
OVARIAN CANCER									
General population[1]									1.1
Dominguez Valentin 2023	Female	0	0	0	2.5 (0.4 to 16.3)	2.5 (0.4 to 16.3)	2.5 (0.4 to 16.3)	2.5 (0.4 to 16.3)	
GASTRIC CANCER									
General population[1]									0.8
Dominguez Valentin 2023	Male					2.7 (0.4 to 17.5)	2.7 (0.4 to 17.5)	2.7 (0.4 to 17.5)	
	Female	0	0	0	0		0	0	**0**
SMALL BOWEL CANCER									
General population[1]									0.3
Dominguez Valentin 2023	Male				3.3 (0.5 to 21.5)	3.3 (0.5 to 21.5)	3.3 (0.5 to 21.5)	3.3 (0.5 to 21.5)	
	Female	0	0	0	0	2.1 (0.3 to 14)	2.1 (0.3 to 14)	2.1 (0.3 to 14)	

Bijlage: Tables 2 to 5, bij module Extracolonische kankerrisico en surveillance bij het Lynch syndroom
Richtlijn Erfelijke darmkanker: Lynch syndroom, polyposis en familiair darmkanker 2025

BILE DUCT / BILIARY TRACT CANCER									
General population[1]									Not available
Dominguez Valentin 2023	Male	0	0	0	0	0	0	0	
	Female	0	0	0	0	0	0	0	
PANCREATIC CANCER									
General population[1]									1.7
Dominguez Valentin 2023	Male	0	0	0	0	0	0	0	
	Female	0	0	0	0	0	0	0	
URETER AND KIDNEY CANCER									
General population[1]									Not available
Dominguez Valentin 2023	Male	0	0	0	0	0	0	5.1 (0.7 to 30.9)	
	Female	0	0	0	0	0	0	0	
URINARY BLADDER CANCER									
General population[1]									2.3
Dominguez Valentin 2023	Male	0	0	0	0	0	0	0	
	Female	0	0	0	0	0	0	0	
PROSTATE CANCER									
General population[1]									12.6
Dominguez Valentin 2023	Male	0	0	3.3 (0.5 to 21.5)	3.3 (0.5 to 21.5)	3.3 (0.5 to 21.5)	3.3 (0.5 to 21.5)	3.3 (0.5 to 21.5)	
BREAST CANCER									
General population[1]									Not reported
Dominguez Valentin 2023	Female	0	0	0	6.0 (2.0 to 17.5)		6.0 (2.0 to 17.5)	12.4 (4.0 to 34.7)	
Fummey 2024	Female	0	0.8 (0 to -3.1)	2.3 (1.0 to 5.1)	5.6 (3.4 to 9.4)	6.2 (3.8 to 10.1)	9.2 (5.8 to 14.3)	9.2 (5.8 to 14.3)	14.4 (6.7 to 29.3)
BRAIN CANCER									
General population[1]									0.5
Dominguez Valentin 2023	Male	0	0	0	0	0	0	0	
	Female	7.3 (1.1 to 41.6)	7.3 (1.1 to 41.6)	7.3 (1.1 to 41.6)	7.3 (1.1 to 41.6)	7.3 (1.1 to 41.6)	7.3 (1.1 to 41.6)	7.3 (1.1 to 41.6)	

Data indicate the cumulative risk and 95% confidence interval.

[1] Data extracted from NCCN guideline 'Genetic/Familial High-Risk Assessment: Colorectal, Endometrial and Gastric' version 3.2024. Reflect lifetime risk data.

[2] Data presented of the full cohorts.

Bijlage: Tables 2 to 5, bij module Extracolonische kankerrisico en surveillance bij het Lynch syndroom
Richtlijn Erfelijke darmkanker: Lynch syndroom, polyposis en familiair darmkanker 2025

[3] Age specific incidences were retrieved from authors records. The following hazard ratios were presented by Ten Broeke (2018):

Type of cancer	Hazard ratio (95% confidence interval)
Endometrial	5.73 (2.98 to 11.0)
Ovarian	1.52 (0.45 to 5.05)
Gastric	2.07 (0.73 to 5.87)
Hepatobiliary	1.02 (0.12 to 8.60)
Bladder	0.61 (0.16 to 2.28)
Ureter and kidney	2.05 (0.77 to 5.45)
Prostate	0.94 (0.46 to 1.93)
Breast	1.30 (0.79 to 2.16)
Brain	2.09 (0.79 to 5.54)